Peptide Receptor Radioligand Therapy (PRRT) is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas


Introduction: Gastrinomas represent a rare group of neuroendocrine tumors usually located in the duodenum or pancreas. They secrete gastrin, which is responsible for the clinical picture of severe acid-related peptic disease and diarrhea, known as the Zollinger-Ellison syndrome (ZES). While symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs) treatment, little data is known regarding the possible anti-tumor effect of the peptide receptor radioligand therapy (PRRT) in gastrinoma patients.

Aim(s): To assess the effect of PRRT on symptom control, gastrin secretion and tumor load in patients with malignant gastrinomas, with progressive disease.

Materials and methods: We have retrospectively studied 11 consecutive patients with metastatic gastrinomas followed at two referral centers in Israel for a mean period of 5 years. The patients were symptomatically treated with PPIs (n=8) and/or with monthly injections of octreotide LAR (30 mg/month) (n=8) or lanreotide Autogel (120 mg/month) (n=1); all patients presented with an ECOG score of 0-1 (1), and received PRRT (90Yttrium- or 177Lutetium-DOTATOC) for progressive disease. Patients had serum gastrin measurements performed pre- and post-treatment, as well as radiological assessment before and every 3-6 months following PRRT, using the RECIST criteria for tumor response (2).

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Grozinsky-Glasberg S, Barak D, Fraenkel M, Müeller J, Shimon I,

Keywords: PRRT, malignant gastrinoma, treatment, anti-tumor effect ,

To read the full abstract, please log into your ENETS Member account.